Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1 Authors: Alexandra Lim, Esther M Peluso, Ian A Downs, Brian H Horwich, Maria A Velez-Velez, Melissa G Lechner Published: 2026 ABSTRACT AbstractImmune checkpoint inhibitor (ICI) cancer therapies targeting programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 enhance antitumor immunity in many cancers. Despite its efficacy, ICI therapy can trigger severe autoimmune attacks across various organ systems, termed immune-related adverse events (irAEs). Antitumor immunity and autoimmunity are tightly linked as demonstrated by the enhanced efficacy of ICI therapy in patients who develop irAEs. Whether patients with preexisting autoimmunity or genetic risk factors for autoimmunity should be offered ICI therapies remains uncertain. We present the case of a patient with autoimmune polyglandular syndrome type 1, caused by a pathogenic autoimmune regulator (AIRE) missense mutation, who was treated with ICI therapy for squamous cell carcinoma of the hard palate. She subsequently developed 3 concurrent irAEs: ICI-hepatitis, ICI-thyroiditis, and ICI-diabetes mellitus. For these irAEs, the patient was treated with immunosuppressants, thyroid hormone replacement, and basal bolus insulin therapy. This case highlights the need for careful evaluation of patients for underlying autoimmune diseases prior to ICI therapy initiation. It also highlights a 2-hit model wherein any impaired central immune tolerance combined with ICI therapy may predispose patients to multiple severe irAEs. Introduction Immune checkpoint inhibitor (ICI) therapies, such as antiprogrammed cell death protein 1 and anti-cytotoxic T-lymphocyte-associated antigen-4, have revolutionized cancer standards of care and efficacy by enhancing T-cell tumor responses. Unfortunately, about 60% to 70% of patients treated with ICI therapies experience autoimmune attacks to healthy tissue as a side effect, termed immune-related adverse events (irAEs) [1]. IrAEs most frequently occur in skin, gastrointestinal, and endocrine organs, although any organ can be affected. Due to the high risk of irAEs in cancer patients treated with ICI therapy, patients with preexisting autoimmunity have largely been excluded from clinical trials and treatment with ICIs [2]. Whether patients with preexisting autoimmunity or genetic predisposition for autoimmunity have an increased risk for the development of irAEs is unknown. Autoimmune polyglandular syndrome type 1 (APS-1) is an autoimmune syndrome that is characterized by hypoparathyroidism, adrenal insufficiency (Addison’s disease), and chronic mucocutaneous candidiasis in addition to other autoimmune manifestations [3]. APS-1 is caused by genetic mutations in the autoimmune regulator (AIRE) gene leading to loss of thymic central tolerance function and increased release of autoreactive T cells that predispose patients to autoimmunity. Here, we describe a patient with APS-1 who developed 3 concurrent severe irAEs following checkpoint inhibitor cancer therapy. Case presentation We present a 32-year-old female with APS-1 who developed multiple irAEs following ICI therapy for squamous cell carcinoma (SCC) of the hard palate. She was diagnosed with APS-1 at age 11, with genetic confirmation of a homozygous pathogenic AIRE mutation (c.254A>G). Her clinical course included GH deficiency (treated from ages 11 to 18), adrenal insufficiency, hypoparathyroidism, and vitamin D deficiency, for which she received glucocorticoids, calcium, and vitamin D supplementation. After transitioning to adult care, glucocorticoids were discontinued following normal ACTH and cortisol testing. At age 31, she developed an abnormal mouth growth, confirmed on biopsy to be SCC of the hard palate. Recurrent chronic mucocutaneous candidiasis infection is a risk factor for palate malignancy in APS-1 [4]. A positron emission tomography-computed tomography scan revealed focal intense fluorodeoxyglucose uptake of the left hard palate, corresponding with her primary malignancy, without evidence of locoregional lymph node or distant metastatic disease. Magnetic resonance imaging of the head and neck confirmed a 22 × 13 × 2 mm (antero-posterior × transverse × cranio-caudal) invasive mass of the left hard palate. Given her young age and localized disease, surgical removal of her palate cancer was recommended. The patient decided against first-line surgical intervention due to concerns for poor postoperative quality of life and elected for neoadjuvant treatment with pembrolizumab to reduce the extent of surgery or radiation therapy needed. She was advised about the potential for autoimmune disease exacerbation with her underlying history of APS-1. The patient received a total of 3 cycles of pembrolizumab. Approximately 3 months after beginning ICI, she was admitted to the hospital for new-onset generalized weakness, lightheadedness, and intermittent diarrhea. Diagnostic assessment On hospital admission, the patient was evaluated for irAEs related to ICI therapy. She denied associated fevers, chills, abdominal pain, nausea, vomiting, melena, or hematochezia. On physical examination, she was jaundiced. Labs revealed elevated aspartate aminotransferase (1083 U/L [SI: 18.05 µkat/L]) (normal range, 13-62 U/L [SI: 0.22-1.03 µkat/L]), alanine aminotransferase (1638 U/L [SI: 27.30 µkat/L]) (normal range, 8-70 U/L [SI: 0.13-1.17 µkat/L]), alkaline phosphatase (999 U/L [SI: 16.65 µkat/L]) (normal range, 37-113 U/L [SI: 0.62-1.88 µkat/L]), and total bilirubin (4.66 mg/dL [SI: 79.7 µmol/L]) (normal range, 0.1-1.2 mg/dL [SI: 1.7-20.5 µmol/L]) (Fig. 1A and 1B). Abdominal ultrasound revealed hepatomegaly with a normal sonographic appearance of the liver parenchyma without evidence of diffuse liver disease or biliary dilatation. Smooth muscle antibodies (<1:20 titer) (normal range, <1:20 titer) and viral hepatitis labs were negative. Her liver tests and medical history were consistent with ICI-hepatitis. Hepatic serum values throughout treatment. (A) Trend of serum AST (red), ALT (blue), and alkaline phosphatase (black) levels throughout treatment. Red arrows indicate time-immunosuppressive treatments were started. Standard range for AST, ALT, and alkaline phosphatase are indicated by dashed lines and shared areas. (B) Serum total (green) and conjugated (black) bilirubin values. Standard range indicated by dashed lines and shaded areas. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase In addition, monitoring labs on ICI therapy revealed new-onset biochemical thyrotoxicosis with a low TSH (<0.02 μLU/mL [SI: <0.02 mIU/L]) (normal range, 0.3-4.7 mclU/mL [SI: 0.3-4.7 mIU/L]) and high free T4 (3.40 ng/dL [SI: 43.8 pmol/L]) (normal range, 0.8-1.70 ng/dL [SI: 10.3-21.9 pmol/L]) (Fig. 2A). She denied tremors, palpitations, weight loss, or heat intolerance. Based on her laboratory data, she was diagnosed with ICI-thyroiditis. Serum thyroid function values. Serum TSH (black) and free T4 (purple) levels measured across treatment period. Shaded bands represent the reference ranges for TSH and T4. Lastly, her hospital admission labs revealed new hyperglycemia (325 mg/dL [SI: 18.0 mmol/L]) (normal range, <99 mg/dL [SI: <5.50 mmol/L]) with concurrent low connecting peptide (C-peptide) (1.0 ng/mL [SI: 0.331 nmol/L]) (normal range, 1.1-4.3 ng/mL [SI: 0.36-1.42 nmol/L]) but no ketoacidosis (Fig. 3). Testing further revealed negative islet antigen-2 antibodies (<5.4 U/mL [SI: <5.4 kU/L]) (normal range, <7.4 U/mL [SI: <7.4 kU/L]), negative islet cell cytoplasmic antibodies (<1:4 titer) (normal range, <1:4 titer), negative zinc transporter 8 antibodies (<10 U/mL [SI: <10 kU/L]) (normal range <15 U/mL [SI: <15 kU/L]) but positive glutamic acid decarboxylase-65 antibodies (>250.0 IU/mL [SI: >250 kIU/L]) (normal range, <5.0 IU/mL [SI: <5.0 kIU/L]). Physical exam revealed a body mass index of 18.95 kg/m2 and no acanthosis nigricans. The patient had no prior antihyperglycemic medication use and had a pre-ICI therapy hemoglobin A1c of 5.7% (normal range, ≤5.7%). Glucose and C-peptide reponses. Serum glucose and C-peptide values during treatment. Dashed and colored regions indicate standard range for glucose and C-peptide. Abbreviation: C-peptide, connecting peptide. Treatment At hospital admission, the patient was started on high-dose prednisone (dosed at 1.5 mg/kg daily) for ICI-hepatitis (Table 1). Despite treatment with increasing IV methylprednisolone (dosed at 2 mg/kg daily), the patient had worsening of her liver function tests and total bilirubin levels. Therefore, tacrolimus 1 mg every 12 hours was added as a secondary therapy and later increased to 3 mg every 12 hours (goal tacrolimus level 10-12 ng/mL [SI: 12.4-14.9 nmol/L]), which led to subsequent downtrend in her liver abnormalities. Due to ongoing cholestasis, she was started on ursodiol 500 mg twice daily. Near hospital discharge, the patient began mycophenolate mofetil 360 mg twice daily due to stagnation of liver tests. Repeat outpatient labs revealed normalization of her aspartate aminotransferase (27 U/L [SI: 0.45 µkat/L]), alanine aminotransferase (57 U/L [SI: 0.95 µkat/L]), alkaline phosphatase (88 U/L [SI: 1.47µkat/L]), and total bilirubin (0.7 mg/dL [SI: 12.0 µmol/L]) with the combined aforementioned therapies (Fig. 1A and 1B). Table 1Immunosuppressive management of ICI-hepatitis and liver biochemical responseTherapyTime from ICI-hepatitis diagnosisDoseRouteScheduleIndicationBiochemical responseMethylprednisone0 days1.5 →2 mg/kg dailyIVOnce dailyFirst-line therapy for ICI-hepatitisContinued rise in aminotransferases and total bilirubinTacrolimus7 days1 mg → 3 mgOralEvery 12 hoursSteroid refractory ICI-hepatitisDowntrend in aminotransferases and bilirubin(goal 10-12 ng/mL)Mycophenolate mofetil8 days360 mgOralTwice dailyIncomplete biochemical recoveryNormalization of aminotransferases, alkaline phosphatase, and total bilirubinUrsodiol12 days500 mgOralTwice dailyPersistent cholestasisStagnation of liver testsAbbreviation: ICI, immune checkpoint inhibitor. Immunosuppressive management of ICI-hepatitis and liver biochemical response Abbreviation: ICI, immune checkpoint inhibitor. The patient also presented with ICI-thyroiditis. In the absence of adrenergic symptoms, the patient was not treated with β-blocker therapy. She subsequently reported fatigue, weakness, and lightheadedness, and laboratory data revealed she had transitioned to hypothyroidism with high TSH (34.1μLU/mL [SI: 34.1 mIU/L]) and low free T4 (0.5 ng/dL [SI: 6.44 pmol/L]). Thyroid peroxidase antibodies were negative (13 IU/mL [SI: 13 kIU/L]) (normal range, <20 IU/mL [SI: <20 kIU/L]). The patient was started on weight-based levothyroxine at 1.4 mcg/kg/day [5]. Repeat TSH (1.4μLU/mL [SI: 1.4 mIU/L]) and free T4 (1.5 ng/dL [SI: 19.3 pmol/L]) normalized with thyroid hormone replacement. For ICI-diabetes mellitus (DM), the patient was started on basal and bolus insulin with improvement in her blood glucose levels to the normal range. The patient was discharged on insulin with a continuous glucose monitor. After 1 month, her C-peptide further downtrended (0.2 ng/mL [SI: 0.066 nmol/L]). The patient continued insulin therapy for ICI-DM at home. Outcome and follow-up After multidisciplinary discussion, ICI therapy was discontinued after 3 cycles in light of 3 new irAEs, and she was counseled to avoid any further ICI therapies in the future. Repeat magnetic resonance imaging of the face, performed 179 days after ICI initiation, revealed interval growth and progression of her hard palate SCC. The mass remeasured 30 × 20 × 8 mm (antero-posterior × transverse × cranio-caudal) centered at the mucosal and submucosal surface of the left aspect of the hard palate with new extension across the midline and new involvement of the alveolar ridge. No lymphadenopathy was noted. Interestingly, 6 months after initiation of immunosuppression and discontinuation of ICI therapy, the patient demonstrated partial recovery of endogenous insulin production with detectable C-peptide of 1.2 ng/mL (SI: 0.40 nmol/L) with blood sugar of 179 mg/dL (SI: 9.94 mmol/L). Bolus mealtime insulin was discontinued, and only low-dose basal insulin was required (2-3 units per day, or <0.1 units/kg/day). She continued on immunosuppression with prednisone (30 mg per day), tacrolimus (2 mg every 12 hours), and mycophenolate mofetil (360 mg twice daily). Discussion Although ICIs have transformed cancer treatment, their safety in patients with preexisting autoimmune disease remains poorly defined. We describe a patient with APS-1 who developed multiple severe irAEs following ICI therapy. APS-1 is classically characterized by mucocutaneous candidal infections, adrenal insufficiency, and hypoparathyroidism, with additional endocrine and nonendocrine autoimmune manifestations [6]. APS-1 is most commonly caused by recessive mutations in AIRE, a transcription factor essential for thymic negative selection through expression of tissue-specific antigens such as thyroglobulin and insulin in medullary thymic epithelial cells (Fig. 4B) [6]. Loss of AIRE function impairs central tolerance, resulting in increased autoreactive T cells and lifelong autoimmune susceptibility. Because ICI therapies enhance T-cell activation, whether patients with APS-1 are at increased risk for developing irAEs remains unknown [7]. Two-hit model whereby loss of central tolerance and ICI therapy in the periphery increases irAEs risk. (A) Schematic of AIRE protein sequence with functional domains and mutation identified in patient with APS-1. The patient described here had a homozygous mutation in the caspase activation and recruitment domain of the AIRE protein at nucleotide position 254 A > G. This mutation results in an amino acid change from tyrosine to cysteine at amino acid position 85 (Y85C). (B) Two-hit model of APS-1 risk for irAEs. Loss-of-function mutations of AIRE decrease AIRE-dependent negative selection in the thymus, leading to an increased release of self-reactive T cells and increased risk of irAEs development with ICI administration. Figure created in Biorender. Abbreviations: APS-1, autoimmune polyglandular syndrome type 1; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event. Prior case reports have described worsened autoimmune damage and unmasking of APS-1 or APS type 2 (APS-2) after ICI. Whereas APS-1 is a rare monogenic disease, APS-2 is a more prevalent polygenic disorder linked to human leukocyte antigen (HLA) susceptibility that classically presents with type 1 diabetes mellitus, autoimmune thyroiditis, and adrenal insufficiency. A recent review compiled 26 case reports describing ICI-induced APS-2 [8]. Of the 26 patients, 92.3% (24/26) developed type 1 diabetes mellitus, 92.3% (24/26) developed thyroid disease, and 23.1% (6/26) developed adrenal insufficiency on ICI therapy. Among the 26 patients, 14 patients were genotyped, of which 71.4% (10/14) were found to have a high-risk HLA allele (HLA-DR4) predisposing them to APS-2. In another case report, a patient with melanoma treated with pembrolizumab developed APS-2 and had a HLA class II genotype HLA-DRB1*04.16, which is another recognized HLA-DR4 serotype associated with APS-2 [9]. Defects in central tolerance might predispose patients to irAEs. Recently, in patients with breast cancer, the addition of anti-RANKL (denosumab) for bone-related metastasis increased the risk of severe grade 3+ irAEs in patients treated with pembrolizumab [10]. Anti-RANKL classically reduces bone absorption but also decreases AIRE-positive medullary thymic epithelial cell development, critical for negative selection [11]. Thus, similar to patients with APS-1 who have faulty thymic negative selection, anti-RANKL increases the risk for severe irAEs, suggesting that loss of central tolerance mechanisms increases the risk for severe irAEs (Fig. 4B). Here we describe a 2-hit model wherein self-tolerance is compromised by 2 factors: a baseline defect in central tolerance and the additional disruption of immune checkpoints through ICI therapy. In our patient with APS-1 treated with pembrolizumab, we observed a rapid and severe development of concurrent ICI-thyroiditis, ICI-hepatitis, and ICI-DM. IrAEs have a significant impact on patient health and quality of life. Therefore, we recommend that ICI therapy be cautiously considered in patients with APS-1 or APS-2. It is important to consider whether underlying APS-1 or APS-2 may be present in patients for whom ICI therapy is recommended. Autoimmunity and antitumor immunity are tightly linked such that increased irAEs frequently correlate with enhanced tumor control [12]. Nonetheless, irAEs can significantly compromise patient quality of life, necessitate treatment discontinuation, and occasionally result in death [1]. Thus, defining patient-specific risk factors is critical for preserving antitumor efficacy while limiting unintended severe immune toxicities. Learning points A 2-hit model involving a baseline defect in central tolerance and the additional disruption of immune checkpoints caused by ICI therapy may cause increased irAEs in at-risk patients. A 2-hit model involving a baseline defect in central tolerance and the additional disruption of immune checkpoints caused by ICI therapy may cause increased irAEs in at-risk patients. Faulty central tolerance mechanisms, as seen in APS-1 due to pathogenic AIRE variants, or APS-2 in association with high-risk HLA genotypes, may contribute to increased irAE risk with concurrent use of ICI therapy. Faulty central tolerance mechanisms, as seen in APS-1 due to pathogenic AIRE variants, or APS-2 in association with high-risk HLA genotypes, may contribute to increased irAE risk with concurrent use of ICI therapy. Patients should be screened for autoimmune disease syndromes, such as underlying APS-1 or APS-2, prior to ICI therapy. Patients should be screened for autoimmune disease syndromes, such as underlying APS-1 or APS-2, prior to ICI therapy.